Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

v3.22.2.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Total
Balance at Jun. 30, 2020   $ 6 $ 207,065 $ (33) $ (150,420) $ (11) $ 56,607
Balance (in shares) at Jun. 30, 2020 6,000 5,603,000          
Capital raises   $ 2 78,274       78,276
Capital raises (in shares)   1,953,000          
Costs to raise capital and warrant exchange     (4,713)       (4,713)
Exercise of stock options     54       $ 54
Exercise of stock options (in shares)   2,000         2,147
Vesting of RSU's     1       $ 1
Conversion of preferred stock to common stock   $ 1 (1)        
Conversion of preferred stock to common stock (in shares) (6,000) 1,157,000          
Share-based compensation     1,586       1,586
Foreign currency translation adjustment       (1)     (1)
Unrealized loss on available-for-sale debt securities       (29)     (29)
Net loss         (23,207) (6) (23,213)
Balance at Jun. 30, 2021   $ 9 282,266 (63) (173,627) (17) 108,568
Balance (in shares) at Jun. 30, 2021   8,715,000          
Sale of preferred stock (in shares) 1,000            
Exercise of stock options     77       $ 77
Exercise of stock options (in shares)   3,000         3,380
Vesting of RSU's (in shares)   9,000          
Warrant issued for Transaction     967       $ 967
Acquisition of remaining portion of iBio CDMO     (68)     18 (50)
Share-based compensation     4,377       4,377
Unrealized loss on available-for-sale debt securities       (150)     (150)
Net loss         (50,303) $ (1) (50,304)
Balance at Jun. 30, 2022   $ 9 $ 287,619 $ (213) $ (223,930)   $ 63,485
Balance (in shares) at Jun. 30, 2022 1,000 8,727,000